Novartis Consumer Health
Indications And Clinical Uses: As a dietary supplement where calcium intake may be inadequate: childhood, adolescence, adulthood, pregnancy, lactation, perimenopausal and postmenopausal women and in the aged.
In the treatment of calcium deficiency states which may occur in diseases such as hypoparathyroidism (acute and chronic), pseudohypoparathyroidism, postmenopausal and senile osteoporosis, rickets and osteomalacia.
Contra-Indications: Hypercalcemia and hypercalciuria (e.g. hyperparathyroidism, vitamin D overdosage, decalcifying tumors such as plasmocytoma, bone metastases); severe renal disease; and in calcium loss due to immobilization. Hypersensitivity to any of the components.
Precautions: In mild hypercalciuria (exceeding 300 mg/ 24 hours) as well as in chronic renal failure, or where there is evidence of stone formation in the urinary tract, adequate checks must be kept on urinary calcium excretion. If necessary, dosage should be reduced or calcium therapy discontinued. In patients prone to formation of calculi in the urinary tract, an increased fluid intake is recommended.
For phenylketonuric patients, consideration should be given to the aspartame content (5 mg/tablet) of Calsan chewable tablets. Calsan tablets and capsules are suitable for sodium and potassium restricted diets. Calsan preparations do not contain sugar and are therefore suitable for diabetic patients requiring calcium supplementation.
High vitamin D intake should be avoided during calcium therapy unless especially indicated.
Drug Interactions: Administration of corticosteroids may interfere with calcium absorption.
Calcium carbonate should not be taken within 3 hours of oral tetracycline or fluoride administration (possible interference of absorption).
Thiazide diuretics cause calcium retention and this may exacerbate hypercalcemia from CaCO3 (calcium carbonate).
Administration of calcium may reduce the response to verapamil and possibly other calcium channel blockers.
Given in large doses to digitalized patients, calcium may increase the risk of cardiac arrhythmias.
Certain dietary substances interfere with the absorption of calcium. These include oxalic acid (found in large quantities in rhubarb and spinach), phytic acid (bran and whole cereals) and phosphorus (milk and other dairy products).
Adverse Reactions: Occasional diarrhea or constipation may occur with high calcium intake.
Symptoms And Treatment Of Overdose: Symptoms and Treatment: Acute overdosage has not been reported. It would be expected to cause gastrointestinal disturbances but not to result in hypercalcemia, except in patients treated with an excessive dose of Vitamin D.
Dosage And Administration: Tablets: chew 1 to 3 chewable tablets/day or as directed by the physician.
Capsules: take 1 to 3 soft gelatin capsules/day with water or as directed by the physician.
Availability And Storage: Capsules: Each off-white oblong soft gelatin capsule, imprinted 500 mg on one side and the CALSAN logo on the other (in green), contains: calcium carbonate 1 250 mg and provides 500 mg (12.5 mmol) elemental calcium. Nonmedicinal ingredients: FD&C blue No. 1, FD&C yellow No. 10, gelatin, glycerin, methyl paraben, polyethylene glycol, propyl paraben, sorbitol and titanium dioxide. Energy: 24.45 kJ (5.85 kcal). Potassium: 0.007 mmol (0.266 mg). Sodium: 0.16 mmol (3.79 mg). Bottles of 100. Keep in a cool, dry place.
Tablets: Each white, scored, double hexagonal chewable tablet, embossed “Ca+500” on one side and “CALSAN” on the other, contains: calcium carbonate 1 250 mg and provides 500 mg (12.5 mmol) elemental calcium. Nonmedicinal ingredients: aspartame, citric acid, flavors, magnesium stearate, mannitol, polyethylene glycol and povidone. Energy: 15.12 kJ (3.6 kcal). Potassium: 0.0017 mmol (0.065 mg). Sodium: 0.18 mmol (4.29 mg). Bottles of 100. (Shown in Product Recognition Section)
CALSAN® Novartis Consumer Health Calcium Carbonate Calcium Supplement